C07C13/36

EGFR INHIBITOR COMPOUNDS

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR INHIBITOR COMPOUNDS

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR INHIBITOR COMPOUNDS

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR inhibitor compounds

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR inhibitor compounds

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR INHIBITOR COMPOUNDS

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR inhibitor compounds

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR inhibitor compounds

Disclosed herein are nitrogen-containing bicyclic compounds of Formula (I), including pharmaceutically acceptable salts thereof, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein. ##STR00001##

EGFR inhibitor compounds

Disclosed herein are nitrogen-containing bicyclic compounds of Formula (I), including pharmaceutically acceptable salts thereof, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein. ##STR00001##

BI-FUNCTIONALIZED DICYCLOPENTADIENE MONOMER AND POLYMER EMBODIMENTS, AND METHODS OF MAKING AND USING SAME

Disclosed herein are embodiments of a bi-functionalized dicyclopentadiene monomer and polymer embodiments formed therefrom. The monomer embodiments exhibit tunability and can be used to form thermally stable homopolymers, copolymers, and/or crosslinked polymers.